Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5084760010 | Aluminium hydroxide 58.2 mg/mL and magnesium hydroxide 19.6 mg/mL and oxetacaine 2 mg/mL oral suspension | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 5084761014 | Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5084762019 | Aluminum hydroxide 58.2 mg/mL and magnesium hydroxide 19.6 mg/mL and oxethazaine 2 mg/mL oral suspension | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | a une forme pharmaceutique (attribut) | suspension orale (forme pharmaceutique) | true | Inferred relationship | Some | ||
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Plays role | Laxative therapeutic role | true | Inferred relationship | Some | ||
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has precise active ingredient | Oxethazaine | true | Inferred relationship | Some | 1 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Oxethazaine | true | Inferred relationship | Some | 1 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 1 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength denominator unit | Milliliter (qualifier value) | true | Inferred relationship | Some | 1 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has precise active ingredient | Aluminium hydroxide (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Aluminium hydroxide (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 2 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength denominator unit | Milliliter (qualifier value) | true | Inferred relationship | Some | 2 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has precise active ingredient | Magnesium hydroxide (substance) | true | Inferred relationship | Some | 3 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Magnesium hydroxide (substance) | true | Inferred relationship | Some | 3 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 3 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | Has concentration strength denominator unit | Milliliter (qualifier value) | true | Inferred relationship | Some | 3 | |
| Product containing precisely aluminium hydroxide 58.2 milligram/milliliter and magnesium hydroxide 19.6 milligram/milliliter and oxetacaine 2 milligram/1 milliliter conventional release oral suspension (clinical drug) | est un(e) (attribut) | Aluminum hydroxide and magnesium hydroxide and oxethazaine only product in oral dose form | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR